|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Faecal incontinence and health related quality of life in inflammatory bowel disease patients: Findings from a tertiary care center in South Asia显示文摘AIM: To analyze the frequency and severity of faecal incontinence(FI) and its effect on the quality of life(QOL) in inflammatory bowel disease(IBD) patients. METHODS: All patients who attended surgical and medical gastroenterology outpatient clinics in a tertiary care center with an established diagnosis of either ulcerative colitis(UC) or Crohn's disease(CD) over a period of 10 mo were included in this study. Before enrollment into the study, the patients were explained about the study and informed consent was obtained. The patients with unidentified colitis were excluded. The data on demographics, disease characteristics, FI(Vaizey score), and quality of life(IBD-Q) were collected. Data were analyzed using SPSS version 21.RESULTS: There were 184 patients(women = 101, 54.9%; UC = 153, 83.2%) with a female preponderance for UC(male/female ratio = 1:1.5) and a male preponderance for CD(male/female = 2:1). Forty-eight(26%) patients reported symptoms of FI. Among the patients with FI, 70.8% were women(n = 34) and 29.2% were men(n = 14) with an average age of 52.7 years(range, 20-78 years). Average age of onset of FI was 48.6(range, 22-74) years. Ten percent(n = 5) reported regular FI. Incontinence to flatus was seen in 33.3%(n = 16), to liquid faeces in 56.2%(n = 27), to solid faeces in 6.2%(n = 3) and to all three in 4.1%(n = 2). Twenty-one percent(n = 10) complained of disruption of their physical and social activity. There was no association between FI and type of IBD. Significant associations were found between FI and age(P = 0.005) and gender(P < 0.001). QOL in our cohort of patients was significantly affected by FI.CONCLUSION: In our study, nearly a quarter of patients reported FI. There was a significant correlation between FI and QOL. Therefore, enquiring about FI in IBD patients can lead to identification of this debilitating condition. This will enable early referral for continence care in this group of patients. | Duminda Subasinghe Navarathna Mudiyanselage Meththananda Navarathna Dharmabandhu Nandadeva Samarasekera | 2016 | World Journal of Gastrointestinal Pharmacology and Therapeutics2016，7，3： | 2 |
| 2 | Fourier Lucas-Kanade algorithm显示文摘 | Lucey S Navarathna R Ashraf A | | 0，，06： | 1 |
| 3 | Dur3 is the major urea transporter in Candida albica and is co-regulated with the urea amidolyase Durl, 2 显示文摘 | Navarathna DH Das A Morschhauser J | 2011 | Microbiology2011，57，1： | 1 |
| 4 | Enhanced pathogenicity of Candida albicans pre treated with subin- hibitory concentrations of fluconazole in a mouse model of disseminated candidiasis显示文摘 | Navarathna DH Hornby JM Hoerrmann N | 2005 | J Antimicrob Chemother2005，56，11： | 1 |
| 5 | Effect of far- nesol on a mouse model of systemic candidiasis,determined by use of a DPP3 knockout mutant of Candida albicans显示文摘 | Navarathna DH Hornby JM Krishnan N | 2007 | Infect Immun2007，75，4： | 1 |
| 6 | Enhanced pathogenicity of Candida albicans pre-treated with subinhibitory concentrations of fluconazole in a mouse model of disseminated candidiasis 显示文摘 | Navarathna D H Homby J M Hoerrmann N | 2005 | J Antimicrob Chemother2005，56，6： | 1 |
| 7 | Enhanced pathogenicity of Candida albicans pre-treated with subinhibitory concentrations of fluconazole in a mouse model of disseminated candidiasis显示文摘 | NAVARATHNA D H HORNBY J M HOERRMANN N | 2005 | J Antimicrob Chemother2005，56，6： | 1 |
| 8 | Effect of farnesol on a mouse model of systemic candidiasis, determined by use of a DPP3 knockout mutant of Candida albicans显示文摘 | NAVARATHNA D H HORNBY J M KRISHNAN N | 2007 | Infect Immun2007，75，4： | 1 |
| 9 | Exogenous farnesol interferes with the normal progression of cytokine expression during candidiasis in a mouse model显示文摘 | NAVARATHNA D H NICHERSON K W DUHAMEL G E | 2007 | Infect Immun2007，75，8： | 1 |
| 10 | Candida albicans tupl is involved in farnesol-mediated inhibition of filamentous- growth induction显示文摘 | Kebaara BW Langford ML Navarathna DH | 2008 | Eukaryot Cell2008，7，6： | 1 |
| 11 | DUR3 isthe major urea transporter in Candida albicans and is co- regulated with the urea amidolyase Durl ,2 显示文摘 | Navarathna D H Das A Morschhaeuser J | 2011 | Microbiol- ogy2011，157，1： | 1 |
| 12 | Effect of farnesol on a mouse model of systemic candidiasis, determined by use of a DPP3 knockout mutant of Candida albi- cans显示文摘 | Navarathna DH Hornby JM Krishnan N | 2007 | Infect Immun2007，75，4： | 1 |
| 13 | Exogenous farnesol interferes with the normal progression of cytokine ex- pression during candidiasis in a mouse model 显示文摘 | Navarathna DH Nickerson KW Duhamel GE | 2007 | Infect Immun2007，75，8： | 1 |
| 14 | Enhanced pathogenicity of Candida albicans pre treated with subinhibitory concentrations of flueonazole in a mouse model of disseminated candidiasis显示文摘 | Navarathna D H Hornby J M Hoerrmann N Parkhurst A M Duhamel G E Nickerson K W | 2005 | J Antimicrob Chemother2005，56，： | 1 |
| 15 | Effect of farnesol on a mouse model of systemic candidiasis,determined by use of a DPP3 knock out mutant of Candida albicans 显示文摘 | Navarathna D H Hornby J M Krishnan N Parkhurst A Duhamel G E Nickerson K W | 2007 | Infect Immun2007，75，： | 1 |
| 16 | Exogenous farnesol W,Duhamel G E,Jerrels T R, interferes with the normal progression of cytokine expression during candidiasis in a mouse model显示文摘 | Navarathna D H Nickerson K Petro TM | 2007 | Infect Immun2007，75，： | 1 |
| 17 | Influence of heteroeyelie and oxime-eontaining farnesol analogs on quorum sensing and pathogenicity in eandida albieans 显示文摘 | Shehepin R Navarathna D Dumitru R | 2008 | Bioorg Med Chem2008，16，4： | 1 |
| 18 | Low-Cost Dye-Sensitized Solar Cells Based on Interconnected FTO-Activated Carbon Nanoparticulate Counter Electrode Showing High Efficiency显示文摘 | Chandana Sampath Kumara Ranasinghe Eranji Nirmada Jayaweera Gamaralalage Rajanya Ashoka Kumara Rajapakse Mudiyanselage Gamini Rajapakse Herath Mudiyanselage Navarathna Bandara Masamichi Yoshimura | 2015 | 材料科学与工程(中英文A版)2015，5，9： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员